Trial Profile
A multi-center retrospective study of Apatinib in patients with un-resectable high-grade osteosarcoma progressing after standard chemotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jun 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Osteosarcoma
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2017 New trial record
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology